Patients who received treatment with inhibitors of complement system factors (such as eculizumab) or treatments with therapy with biological immunomodulators (example tocilizumab, etanercept, infliximab) in the 4 weeks prior to the admission in the study, patients involved in other clinical studies, patients with active tissue or systemic bacterial or fungal infection, pregnant or breastfed patients, patients with more than ten days of symptoms.

Patients who received treatment with inhibitors of complement system factors (such as eculizumab) or treatments with therapy with biological immunomodulators (example tocilizumab, etanercept, infliximab) in the 4 weeks prior to the admission in the study, patients involved in other clinical studies, patients with active tissue or systemic bacterial or fungal infection, pregnant or breastfed patients, patients with more than ten days of symptoms.